Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

References

• Brusselle GG, Koppelman GH, Taichman DB. Biologic therapies for severe asthma. Taichman DB, editor. N Engl J Med. 2022;386(2):157–171. Available from: http://www.nejm.org/doi/10.1056/NEJMra2032506
   PubMed Web of Science ®Google Scholar
• Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med [Internet]. 2011;154(9):573–582. doi: 10.7326/0003-4819-154-9-201105030-00002
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet [Internet]. 2012;380:651–659. Available from. doi: http://dx.doi.org/10.1016/S0140-6736(12)60988-X
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med [Internet]. 2014;371(13):1198–1207. doi: 10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet [Internet]. 2016;388(10056):2128–2141. doi: 10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet [Internet]. 2016;388(10056):2115–2127. doi: 10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Maspero J, Adir Y, Al-Ahmad M, et al. Type 2 inflammation in asthma and other airway diseases. ERJ Open Res [Internet]. 2022;8(3):00576–02021. doi: 10.1183/23120541.00576-2021
   PubMedGoogle Scholar
• Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy [Internet]. 2020;50(1):5–14. doi: 10.1111/cea.13491
   PubMed Web of Science ®Google Scholar
• Tenero L, Rossignoli S, Piacentini G. Severe asthma: when to resort to biological agents. Pediatr Allergy Immunol. 2020;31(Suppl S24):37–39. doi: 10.1111/pai.13162
   PubMedGoogle Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med [Internet]. 2018;378(26):2486–2496. doi: 10.1056/NEJMoa1804092
   PubMed Web of Science ®Google Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med [Internet]. 2018;378(26):2475–2485. doi: 10.1056/NEJMoa1804093
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet [Internet]. 2019;394:1638–1650. Available from: http://dx.doi.org/10.1016/S0140-6736(19)31881-1
   PubMed Web of Science ®Google Scholar
• Bachert C, Mannent L, Naclerio RM, et al. Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis. JAMA [Internet]. 2016;315(5):469. doi: 10.1001/jama.2015.19330
   Google Scholar
• Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet [Internet]. 2016;387(10013):40–52. doi: 10.1016/S0140-6736(15)00388-8
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet [Internet]. 2017;389(10086):2287–2303. doi: 10.1016/S0140-6736(17)31191-1
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med [Internet]. 2016;375(24):2335–2348. doi: 10.1056/NEJMoa1610020
   PubMed Web of Science ®Google Scholar
• Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022;387(25):2317–2330. doi: 10.1056/NEJMoa2205982
   PubMed Web of Science ®Google Scholar
• Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet [Internet]. 2022;400(10356):908–919. doi: 10.1016/S0140-6736(22)01539-2
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Maspero JF, Katelaris CH, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med [Internet]. 2021;385(24):2230–2240. doi: 10.1056/NEJMoa2106567
   PubMed Web of Science ®Google Scholar
• Campisi R, Crimi C, Nolasco S, et al. Real-world experience with dupilumab in severe asthma: one-year data from an Italian named patient program. J Asthma Allergy [Internet]. 2021;14:575–583. Available from: https://www.dovepress.com/real-world-experience-with-dupilumab-in-severe-asthma-one-year-data-fr-peer-reviewed-fulltext-article-JAA
   PubMed Web of Science ®Google Scholar
• Dupin C, Belhadi D, Guilleminault L, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort. Clin Exp Allergy [Internet]. 2020;50(7):789–798. doi: 10.1111/cea.13614
   PubMed Web of Science ®Google Scholar
• Renner A, Marth K, Patocka K, et al. Dupilumab rapidly improves asthma control in predominantly anti‐IL5/IL5R pretreated Austrian real‐life severe asthmatics. Immun Inflamm Dis [Internet]. 2021;9(3):624–627. doi: 10.1002/iid3.434
   PubMed Web of Science ®Google Scholar
• Nowsheen S, Darveaux JI. Real-world efficacy and safety of dupilumab use in the treatment of asthma. Ann Allergy Asthma Immunol. 2021;127(1):147–149. doi: 10.1016/j.anai.2021.04.011
   PubMed Web of Science ®Google Scholar
• Mümmler C, Munker D, Barnikel M, et al. Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. J Allergy Clin Immunol Pract. 2021;9(3):1177–1185.e4. doi: 10.1016/j.jaip.2020.09.014
   PubMedGoogle Scholar
• Pelaia C, Benfante A, Busceti MT, et al. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps. Front Immunol. 2023;14:1121237. doi: 10.3389/fimmu.2023.1121237
   PubMed Web of Science ®Google Scholar
• Castilla-Martínez M, Andújar-Espinosa R, Flores-Martín I, et al. Early effectiveness of dupilumab in patients with type 2 severe asthma: a prospective real-life study. J Investig Allergol Clin Immunol. 2023;33(2):126–128. doi: 10.18176/jiaci.0872
   PubMed Web of Science ®Google Scholar
• Mümmler C, Dünzelmann K, Kneidinger N, et al. Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. Clin Transl Allergy. 2021;11(5):e12049. doi: 10.1002/clt2.12049
   PubMed Web of Science ®Google Scholar
• van der Lans RJL, Fokkens WJ, GFJPM A, et al. Real-life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps. Allergy. 2022;670–674. doi: 10.1111/all.15134
   PubMed Web of Science ®Google Scholar
• Mustafa SS, Vadamalai K, Scott B, et al. Dupilumab as add-on therapy for chronic rhinosinusitis with nasal polyposis in aspirin exacerbated respiratory disease. Am J Rhinol Allergy. 2021;35(3):399–407. doi: 10.1177/1945892420961969
   PubMed Web of Science ®Google Scholar
• Pelaia C, Lombardo N, Busceti MT, et al. Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis. J Asthma Allergy. 2021;14:1165–1172. doi: 10.2147/JAA.S328988
   PubMed Web of Science ®Google Scholar
• Cantone E, De Corso E, Ricciardiello F, et al. Olfaction recovery following dupilumab is independent of nasal polyp reduction in CRSwNP. J Pers Med. 2022;12(8):12. doi: 10.3390/jpm12081215
   Web of Science ®Google Scholar
• Ottaviano G, Saccardo T, Roccuzzo G, et al. Effectiveness of dupilumab in the treatment of patients with uncontrolled severe CRSwNP: a “real-life” observational study in naïve and post-surgical patients. J Pers Med. 2022;12(9):12. doi: 10.3390/jpm12091526
   Web of Science ®Google Scholar
• Ottaviano G, De Corso E, Cantone E, et al. Measuring nasal patency and the sense of smell in CRSwNP patients treated with Dupilumab. J Pers Med. 2023;13(2):234. doi: 10.3390/jpm13020234
   PubMed Web of Science ®Google Scholar
• Bellocchi G, Loperfido A, Passali FM, et al. Biologics in severe uncontrolled chronic rhinosinusitis with nasal polyps: a bicentric experience. Acta Biomed. 2023;94(5):e2023227. doi: 10.23750/abm.v94i5.14745
   PubMedGoogle Scholar
• Torretta S, De Corso E, Nava N, et al. Proposal for a structured outpatient clinic for dupilumab treatment in chronic rhinosinusitis with nasal polyps in the first year of treatment. J Pers Med. 2022;12(10):12. doi: 10.3390/jpm12101734
   Web of Science ®Google Scholar
• Galletti C, Barbieri MA, Ciodaro F, et al. Effectiveness and safety profile of dupilumab in chronic rhinosinusitis with nasal polyps: real-life data in tertiary care. Pharmaceuticals (Basel). 2023;16(4):630. doi: 10.3390/ph16040630
   PubMedGoogle Scholar
• De Corso E, Pasquini E, Trimarchi M, et al. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy. 2023;78(10):2669–2683. doi: 10.1111/all.15772
   PubMed Web of Science ®Google Scholar
• Kimura A, Takeda A, Ikebukuro T, et al. Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. J Ophthalmic Inflamm Infect. 2021;11(1):0–3. doi: 10.1186/s12348-020-00234-y
   Web of Science ®Google Scholar
• Eger K, Pet L, Weersink EJM, et al. Complications of switching from anti–IL-5 or anti–IL-5R to dupilumab in corticosteroid-dependent severe asthma. J Allergy Clin Immunol Pract [Internet]. 2021;9:2913–2915. Available from: https://doi.org/10.1016/j.jaip.2021.02.042
   PubMed Web of Science ®Google Scholar
• Lommatzsch M, Stoll P, Winkler J, et al. Eosinophilic pleural effusion and stroke with cutaneous vasculitis: two cases of dupilumab-induced hypereosinophilia. Allergy: Eur J Allergy Clin Immunol. 2021;76(9):2920–2923. doi: 10.1111/all.14964
   Google Scholar
• Descamps V, Deschamps L, El Khalifa J, et al. Eosinophilic vasculitis associated with persistent dupilumab-induced hypereosinophilia in severe asthma. Respir Med Res. 2021;79:100821–102022. doi: 10.1016/j.resmer.2021.100821
   PubMedGoogle Scholar
• Briegel I, Felicio-Briegel A, Mertsch P, et al. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. The Journal Of Allergy And Clinical Immunology: In Practice. 2021;9(12):4477–4479. Available from: https://doi.org/10.1016/j.jaip.2021.07.049
   PubMed Web of Science ®Google Scholar
• Trimarchi M, Vinciguerra A, Rampi A, et al. Studio prospettico sull’efficacia di dupilumab per rinosinusite cronica con infiammazione di tipo 2. Acta Otorhinolaryngol Ital. 2022;42(6):538–544. doi: 10.18176/jiaci.0872
   PubMedGoogle Scholar
• Ottaviano G, De Corso E, Saccardo T, et al. Effectiveness of dupilumab in the Treatment of Adult and older Adult patients with severe, uncontrolled CRSwNP. J Pers Med. 2023;13(8):1241. doi: 10.3390/jpm13081241
   PubMed Web of Science ®Google Scholar
• Nitro L, Bulfamante AM, Rosso C, et al. Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review. Acta Otorhinolaryngol Ital. 2022;42(3):199–204. doi: 10.14639/0392-100X-N1911
   PubMed Web of Science ®Google Scholar
• Brkic FF, Liu DT, Rücklinger I, et al. Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis. J Otolaryngol - Head Neck Surg. 2023;52(1):75. doi: 10.1186/s40463-023-00660-7
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Ford LB, Maspero JF, et al. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study. Lancet Respir Med [Internet]. 2021. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2213260021003222
   Web of Science ®Google Scholar
• Domingo C, Rabe KF, Price D, et al. Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose. ERJ Open Res. 2023;9(6):00056–2023. doi: 10.1183/23120541.00056-2023
   PubMedGoogle Scholar
• Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: Current and future perspectives. Paediatr Drugs. 2019;21(4):215–237. doi: 10.1007/s40272-019-00345-7
   PubMed Web of Science ®Google Scholar
• Manti S, Giallongo A, Pecora G, et al. Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: a prospective study. Pediatr Pulmonol. 2023;58(4):1085–1091. doi: 10.1002/ppul.26298
   PubMed Web of Science ®Google Scholar
• Menzella F, Montanari G, Patricelli G, et al. A case of chronic eosinophilic pneumonia in a patient treated with dupilumab. Ther Clin Risk Manag [Internet]. 2019;15:869–875. Available from: https://www.dovepress.com/a-case-of-chronic-eosinophilic-pneumonia-in-a-patient-treated-with-dup-peer-reviewed-article-TCRM
   PubMed Web of Science ®Google Scholar
• Ikeda M, Ohshima N, Kawashima M, et al. Severe asthma where eosinophilic granulomatosis with polyangiitis became apparent after the discontinuation of Dupilumab. Intern Med. 2022;61(5):755–759. doi: 10.2169/internalmedicine.7990-21
   PubMed Web of Science ®Google Scholar
• Hu JK, Yaghi M, Milikowski C, et al. Eosinophilic granulomatosis and polyangiitis unmasked by dupilumab. Int J Dermatol. 2023;62(6):839–840. doi: 10.1111/ijd.16670
   PubMed Web of Science ®Google Scholar
• Caminati M, Fassio A, Alberici F, et al. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: report from the European EGPA study group. Allergy [Internet]. 2023. Available from: https://onlinelibrary.wiley.com/doi/10.1111/all.15934
   Web of Science ®Google Scholar
• Olaguibel JM, Sastre J, Rodríguez JM, et al. Eosinophilia induced by blocking the IL-4/IL-13 Pathway: potential mechanisms and clinical outcomes. J Investig Allergol Clin Immunol. 2022;32(3):165–180. doi: 10.18176/jiaci.0823
   PubMed Web of Science ®Google Scholar
• Vinciguerra A, Rampi A, Yacoub M-R, et al. Hypereosinophilia management in patients with type 2 chronic rhinosinusitis treated with dupilumab: preliminary results. Eur Arch Oto-Rhino-Laryngology. 2022;279(11):5231–5238. doi: 10.1007/s00405-022-07389-5
   PubMed Web of Science ®Google Scholar
• Caminati M, Olivieri B, Dama A, et al. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. Expert Rev Respir Med [Internet]. 2022:1–9. Available from: https://doi.org/10.1080/17476348.2022.2090342
   PubMed Web of Science ®Google Scholar
• Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. doi: 10.1016/j.jaip.2022.05.019
   PubMed Web of Science ®Google Scholar
• Rossi M, Bettolini L, Artelli GL, et al. Dupilumab treatment efficacy and impact on clinical scores, serum biomarkers, and itch in adult patients with atopic dermatitis: a retrospective analysis. J Asthma Allergy. 2023;16:1233–1240. doi: 10.2147/JAA.S433515
   PubMedGoogle Scholar
• Caminati M, Scarpieri E, Maule M, et al. Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis. Rheumatology (Oxford). 2023. doi:10.1093/rheumatology/kead479
   PubMed Web of Science ®Google Scholar
• Molina B, Padoan R, Urban ML, et al. Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study. Ann Rheum Dis. 2023;82(12):1587–1593. doi: 10.1136/ard-2023-224756
   PubMedGoogle Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines—recommendations for severe asthma. Allergy. 2021;76(1):14–44. doi: 10.1111/all.14425
   PubMed Web of Science ®Google Scholar
• Buhl R, Bel E, Bourdin A, et al. Effective management of severe asthma with biologic medications in adult patients: a Literature Review and international expert opinion. J Allergy Clin Immunol Pract. 2022;10(2):422–432. doi: 10.1016/j.jaip.2021.10.059
   PubMed Web of Science ®Google Scholar
• Wang E, Wechsler ME. A rational approach to compare and select biologic therapeutics in asthma. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2022;128(4):379–389. doi: 10.1016/j.anai.2022.01.024
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Al-Ahmad M, Bjermer L, et al. Systemic corticosteroids in asthma: a call to action from World Allergy Organization and respiratory effectiveness group. World Allergy Organ J. 2022;15(12):100726. doi: 10.1016/j.waojou.2022.100726
   PubMed Web of Science ®Google Scholar
• Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the severe asthma network in Italy (SANI) registry. World Allergy Organ J. 2019;12(1):100007. doi: 10.1016/j.waojou.2018.12.001
   PubMed Web of Science ®Google Scholar